de Almeida Filho T P, Maia Filho P A, Barbosa Maritza Cavalcante, Dutra Luana Letícia Alves, Castro Marilena Facundo de, Duarte Fernando Barroso, Quixadá Acy Telles de Souza, Lemes Romélia Pinheiro Gonçalves
Departament of Hematology, Walter Cantidio University Hospital, Fortaleza, Ceara Brazil.
Departament of Hematology, Walter Cantidio University Hospital, Fortaleza, Ceara Brazil.
Hematol Transfus Cell Ther. 2019 Apr-Jun;41(2):114-118. doi: 10.1016/j.htct.2018.10.003. Epub 2019 Feb 16.
In this study, we evaluated the influence of the transcript type on hematological and clinical parameters, as well as the event-free survival of 50 patients in the Chronic myeloid leukemia chronic phase.
We reviewed the medical records of 55 patients with Chronic myeloid leukemia. The eligibility criteria were based on the availability of hematological and clinical baseline data in the medical records. Data on BCR-ABL transcripts were obtained from medical records.
Eighteen patients (36%) had the b2a2 transcript, 24 (48%) had b3a2 and 8 (16%) had b2a2/b3a2. The median platelet count for transcripts b2a2, b3a2 and b2a2/b3a2 was 320.65×10/L, 396×10/L, and 327.05×10/L, respectively (p=0.896). We could not find any differences in relation to the other hematological parameters, when compared to the transcript type. Comparison between spleen and liver size and type of transcript did not differ inside the groups (p=0.395 and p=0.647, respectively) and the association between risk scores and transcript type did not show statistical significance (p>0.05). The 21-month probability for event-free survival was 21%, 48% and 66% for the transcripts b2a2, b3a2 and b2a2/b3a2 respectively (p=0.226) CONCLUSION: We conclude that the expression BCR-ABL transcripts have no influence on hematological, clinical and event-free survival parameters of patients in the Chronic myeloid leukemia chronic phase.
在本研究中，我们评估了转录本类型对慢性髓性白血病慢性期50例患者血液学和临床参数以及无事件生存期的影响。
我们回顾了55例慢性髓性白血病患者的病历。纳入标准基于病历中血液学和临床基线数据的可获取性。BCR-ABL转录本的数据从病历中获取。
18例患者（36%）有b2a2转录本，24例（48%）有b3a2转录本，8例（16%）有b2a2/b3a2转录本。转录本b2a2、b3a2和b2a2/b3a2的血小板计数中位数分别为320.65×10⁹/L、396×10⁹/L和327.05×10⁹/L（p = 0.896）。与转录本类型相比，我们未发现其他血液学参数有任何差异。脾和肝大小与转录本类型之间的组内比较无差异（p分别为0.395和0.647），风险评分与转录本类型之间的关联无统计学意义（p>0.05）。转录本b2a2、b3a2和b2a2/b3a2的21个月无事件生存概率分别为21%、48%和66%（p = 0.226）。结论：我们得出结论，BCR-ABL转录本的表达对慢性髓性白血病慢性期患者的血液学、临床和无事件生存参数无影响。
